Parkman Healthcare Partners LLC Purchases Shares of 50,672 Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Parkman Healthcare Partners initiated a position in Alnylam Pharmaceuticals by purchasing 50,672 shares worth approximately $15.3 million. Institutional investors collectively own 92.97% of the company.
• Alnylam reported quarterly EPS of $1.84, exceeding estimates of $1.63, while revenue rose 66.9% year over year to $1.29 billion, slightly below consensus.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $386.14, despite several recent target-price reductions.

Parkman Healthcare Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,672 shares of the biopharmaceutical company's stock, valued at approximately $15,254,000. Alnylam Pharmaceuticals makes up approximately 1.6% of Parkman Healthcare Partners LLC's portfolio, making the stock its 25th biggest holding.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. iA Global Asset Management Inc. boosted its position in Alnylam Pharmaceuticals by 979.5% in the fourth quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company's stock valued at $7,070,000 after buying an additional 16,133 shares in the last quarter. SCS Capital Management LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $34,784,000. Hussman Strategic Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $2,505,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $50,773,000. Finally, Hsbc Holdings PLC raised its stake in shares of Alnylam Pharmaceuticals by 22.6% in the fourth quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company's stock valued at $35,675,000 after acquiring an additional 16,503 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $236.01 on Tuesday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The firm has a market cap of $31.58 billion, a P/E ratio of 43.87 and a beta of 0.30. The firm has a 50 day simple moving average of $265.98 and a 200 day simple moving average of $296.21. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business's revenue for the quarter was up 66.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.51) EPS. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the business's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on ALNY. Stifel Nicolaus reduced their target price on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a "buy" rating on the stock in a report on Friday, July 31st. JPMorgan Chase & Co. dropped their price target on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an "overweight" rating for the company in a report on Friday, July 31st. Oppenheimer cut their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. Morgan Stanley reduced their price objective on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an "equal weight" rating on the stock in a research note on Friday, July 31st. Finally, Barclays decreased their target price on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an "overweight" rating on the stock in a report on Monday, August 3rd. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $386.14.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source